The original version of this article contained a mistake in the figure. The Ca 2 + confocal image for the 2-APB/Apicidin-120 min in Fig. 5d is incorrect. The correction does not influence either the validity of the published data or the conclusion described in the article. The corrected Fig. 5d is given below.
The original article can be found online at https ://doi.org/10.1007/ s1049 5-012-0755-9. ]) were calculated as described in Materials and Methods and plotted. c Neuro-2a cells were loaded with Fura-2AM and treated with apicidin at 10 min intervals for 2 h period in the presence or absence of 20 µM 2-APB or 10 µM BAPTA-AM. Fluorescence was monitored at 37 °C with a fluorescent plate reader. d Neuro-2a cells were loaded with Fura-2AM and treated with apicidin for 10 min or 120 min in the presence or absence of 2-APB or BAPTA-AM. e Neuro-2a cells were incubated in the presence of 2-APB or BAPTA-AM for 1 h and followed by apicidin or TG for 24 h. Cells were harvested and assessed for cell viability by the MTT assay. *P < 0.01 compared with vehicle-treated control cells.
# P < 0.01 compared with apicidin-or TG-treated cells without 2-APB or BAPTA-AM. n = 3 for each experimental group (a-e). f Neuro-2a cells were incubated in the presence or absence of the 2-APB or BAPTA-AM for 1 h and followed by apicidin or TG for 1 h (for P-eIF2) or 24 h (for CHOP and ATF6α(p90)). Cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6α(p90), P-eIF2α, and β-actin. All bands in the blots (f) were normalized to the level of β-actin in each lane and the fold band intensity was written under each band. Results shown are representative of those obtained in more than three independent experiments
